title: Profile of mirabegron in the treatment of overactive bladder: place in therapy.
abstract: Mirabegron is a relatively new drug introduced to treat overactive bladder syndrome. It can be used either on its own or as part of a combination. This drug has been extensively studied, with a good number of Phase II and Phase III trials showing promising outcomes. These studies show that mirabegron is an effective, well-tolerated drug, which could have some adverse effects of concern. In this review, we look at the trials on mirabegron, as well as its pharmacokinetics, mechanism of action, and side effects as documented in the literature.
authors.affiliation: Female and Functional Urology Unit, Bristol Urological Institute, Bristol, UK.
authors.forename: Ala'a
authors.initials: A
authors.lastname: Sharaf
authors.affiliation: Female and Functional Urology Unit, Bristol Urological Institute, Bristol, UK.
authors.forename: Hashim
authors.initials: H
authors.lastname: Hashim
mesh_terms: D000083:Acetanilides / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D058667:Adrenergic beta-3 Receptor Agonists / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D013844:Thiazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
chemical_list: D000083:Acetanilides; D058667:Adrenergic beta-3 Receptor Agonists; D013844:Thiazoles; C520025:mirabegron
keywords: antimuscarinics; mirabegron; overactive bladder disorder